Triazoloquinazoline CDK Inhibitors With Improved Stability and Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CDK inhibitors face challenges such as lack of efficacy in solid tumors, toxicity issues, and insufficient selectivity for CDK subtypes, limiting their effectiveness in treating CDK-related diseases.
Innovation Solution
Development of 1H-[1,2,3]triazolo[4,5-h]quinazoline compounds with strong inhibitory activity against CDK, enhancing metabolic stability and clearance rates compared to existing drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CDK inhibitors are used, then CDK inhibitory activity is achieved, but metabolic stability and clearance rates are insufficient
Solution Approach 1:
The patent modifies the chemical structure of CDK inhibitors by introducing specific substituent groups (R1, R2, R3) and ring systems (ring A, ring B) to optimize metabolic stability and clearance rates. The compounds of formula (I) employ parameter changes in molecular structure to achieve improved pharmacokinetic properties while maintaining CDK inhibitory activity.
2Reliability
If existing CDK inhibitors are used, then cell cycle regulation is affected, but selectivity for CDK subtypes is insufficient leading to toxicity
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at different positions (R1, R2, R3) of the core triazoloquinazoline structure to enhance selectivity for specific CDK subtypes. The differentiated substitution patterns at various molecular locations allow selective binding to target CDK isoforms while reducing off-target effects and toxicity.
Solution Approach 2:
Instead of designing broad-spectrum CDK inhibitors that block all CDK subtypes, the patent inverts the approach by designing selective inhibitors that target specific CDK subtypes (such as CDK4/6 or CDK9) with high precision. This selective inhibition strategy reduces toxicity by avoiding non-specific CDK blockade while maintaining therapeutic efficacy.
3Reliability
If existing CDK inhibitors are used, then tumor cell cycle progression is inhibited, but efficacy in solid tumors is insufficient
Solution Approach 1:
The patent designs compounds with universal applicability across different tumor types by optimizing the core triazoloquinazoline structure to inhibit multiple CDK subtypes involved in cell cycle regulation. The compounds of formula (I) are designed to target CDK4, CDK6, and/or CDK9, providing broad-spectrum anti-tumor activity that addresses the limitations of subtype-specific inhibitors in solid tumor treatment.
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
Provided are 1H-[1,2,3]triazolo[4,5-H]quinazoline compounds of general formula (I), and the compounds can be used for treating cell proliferation disorders. The compounds are effective inhibitors of cyclin-dependent kinases (CDKs).